Skip to content
← All treatment topics

TREATMENT READING

Non-Hodgkin Lymphoma

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

31 sections
  1. Certain factors affect prognosis (chance of recovery) and treatment options.
  2. Non-Hodgkin lymphomas may be grouped for treatment according to whether the cancer is indolent or aggressive, whether affected lymph nodes are next to each other in the body, and whether the cancer is newly diagnosed or recurrent.
  3. Non-Hodgkin lymphoma can recur (come back) after it has been treated.
  4. Treatment Option Overview
  5. Key Points
  6. There are different types of treatment for patients with non-Hodgkin lymphoma.
  7. Patients with non-Hodgkin lymphoma should have their treatment planned by a team of health care providers who are experts in treating lymphomas.
  8. Treatment for non-Hodgkin lymphoma may cause side effects.
  9. The following types of treatment are used:
  10. Radiation therapy
  11. Chemotherapy
  12. Immunotherapy
  13. Targeted therapy
  14. Plasmapheresis
  15. Watchful waiting
  16. Antibiotic therapy
  17. Surgery
  18. Stem cell transplant
  19. New types of treatment are being tested in clinical trials.
  20. Vaccine therapy
  21. Patients may want to think about taking part in a clinical trial.
  22. Patients can enter clinical trials before, during, or after starting their cancer treatment.
  23. Follow-up tests may be needed.
  24. Treatment of Indolent Non-Hodgkin Lymphoma
  25. Treatment of Aggressive Non-Hodgkin Lymphoma
  26. Treatment of Lymphoblastic Lymphoma
  27. Treatment of Burkitt Lymphoma
  28. Treatment of Recurrent Non-Hodgkin Lymphoma
  29. Treatment of Non-Hodgkin Lymphoma During Pregnancy
  30. Indolent Non-Hodgkin Lymphoma During Pregnancy
  31. Aggressive Non-Hodgkin Lymphoma During Pregnancy

For patients · General Information About Non-Hodgkin Lymphoma

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

The prognosis and treatment options depend on the following:

The patient's signs and symptoms, including whether or not they have B symptoms (fever for no known reason, weight loss for no known reason, or drenching night sweats).

The stage of the cancer (the size of the cancer tumors and whether the cancer has spread to other parts of the body or lymph nodes).

Sources: stage

The type of non-Hodgkin lymphoma.

The amount of lactate dehydrogenase (LDH) in the blood.

Whether there are certain changes in the genes.

The patient’s age, sex, and general health.

Whether the lymphoma is newly diagnosed, continues to grow during treatment, or has recurred (come back).

Sources: recurred

For non-Hodgkin lymphoma during pregnancy, treatment options also depend on:

The wishes of the patient.

Which trimester of pregnancy the patient is in.

Whether the baby can be delivered early.

Some types of non-Hodgkin lymphoma spread more quickly than others do. Most non-Hodgkin lymphomas that occur during pregnancy are aggressive. Delaying treatment of aggressive lymphoma until after the baby is born may lessen the mother's chance of survival. Immediate treatment is often recommended, even during pregnancy.

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

For patients · Stages of Non-Hodgkin Lymphoma

Non-Hodgkin lymphomas may be grouped for treatment according to whether the cancer is indolent or aggressive, whether affected lymph nodes are next to each other in the body, and whether the cancer is newly diagnosed or recurrent.

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

For more information on the types of indolent (slow-growing) and aggressive (fast-growing) non-Hodgkin lymphoma, see the General Information section.

Sources: indolent · aggressive · General Information

Non-Hodgkin lymphoma can also be described as contiguous or noncontiguous:

Sources: contiguous · noncontiguous

Contiguous lymphomas: Lymphomas in which the lymph nodes with cancer are next to each other.

Sources: Lymphomas · lymph nodes

Noncontiguous lymphomas: Lymphomas in which the lymph nodes with cancer are not next to each other, but are on the same side of the diaphragm.

Sources: diaphragm

For patients · Stages of Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma can recur (come back) after it has been treated.

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

The lymphoma may come back in the lymph system or in other parts of the body. Indolent lymphoma may come back as aggressive lymphoma. Aggressive lymphoma may come back as indolent lymphoma.

For patients

Treatment Option Overview

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

There are different types of treatment for patients with non-Hodgkin lymphoma.

Patients with non-Hodgkin lymphoma should have their treatment planned by a team of health care providers who are experts in treating lymphomas.

Treatment for non-Hodgkin lymphoma may cause side effects.

The following types of treatment are used:

The following types of treatment are used:

Radiation therapy

Chemotherapy

Immunotherapy

Targeted therapy

Plasmapheresis

Watchful waiting

Antibiotic therapy

Surgery

Stem cell transplant

New types of treatment are being tested in clinical trials.

New types of treatment are being tested in clinical trials.

Vaccine therapy

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Follow-up tests may be needed.

For patients · Treatment Option Overview

There are different types of treatment for patients with non-Hodgkin lymphoma.

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

Different types of treatment are available for patients with non-Hodgkin lymphoma. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

Sources: non-Hodgkin lymphoma · standard · clinical trials · research study · cancer

For pregnant women with non-Hodgkin lymphoma, treatment is carefully chosen to protect the fetus. Treatment decisions are based on the mother’s wishes, the stage of the non-Hodgkin lymphoma, and the trimester of the pregnancy. The treatment plan may change as the signs and symptoms, cancer, and pregnancy change. Choosing the most appropriate cancer treatment is a decision that ideally involves the patient, family, and health care team.

Sources: pregnant · fetus · stage · signs · symptoms

For patients · Treatment Option Overview

Patients with non-Hodgkin lymphoma should have their treatment planned by a team of health care providers who are experts in treating lymphomas.

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

Treatment will be overseen by a medical oncologist, a doctor who specializes in treating cancer, or a hematologist, a doctor who specializes in treating blood cancers. The medical oncologist may refer you to other health care providers who have experience and are experts in treating non-Hodgkin lymphoma and who specialize in certain areas of medicine. These may include the following specialists:

Sources: medical oncologist · hematologist · blood cancers · health care providers · medicine · specialists

Neurosurgeon.

Sources: Neurosurgeon

Neurologist.

Sources: Neurologist

Radiation oncologist.

Sources: Radiation oncologist

Endocrinologist.

Sources: Endocrinologist

Rehabilitation specialist.

Sources: Rehabilitation specialist

Fertility specialist.

Sources: Fertility specialist

Other oncology specialists.

Sources: oncology

For patients · Treatment Option Overview

Treatment for non-Hodgkin lymphoma may cause side effects.

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

To learn more about side effects that begin during treatment for cancer, visit Side Effects.

Sources: side effects · Side Effects

Side effects from cancer treatment that begin after treatment and continue for months or years are called late effects. Treatment with chemotherapy, radiation therapy, or stem cell transplant for non-Hodgkin lymphoma may increase the risk of late effects.

Sources: late effects · chemotherapy · radiation therapy · stem cell transplant

Late effects of cancer treatment may include the following:

Heart problems.

Infertility (inability to have children).

Sources: Infertility

Loss of bone density.

Sources: bone density

Neuropathy (nerve damage that causes numbness or trouble walking).

Sources: Neuropathy · nerve

A second cancer, such as:

Sources: second cancer

A second cancer, such as:

Lung cancer.

Sources: Lung cancer

Brain cancer.

Kidney cancer.

Sources: Kidney cancer

Bladder cancer.

Sources: Bladder cancer

Melanoma.

Sources: Melanoma

Hodgkin lymphoma.

Sources: Hodgkin lymphoma

Myelodysplastic syndrome.

Sources: Myelodysplastic syndrome

Acute myeloid leukemia.

Sources: Acute myeloid leukemia

Some late effects may be treated or controlled. It is important to talk with your doctor about the effects cancer treatment can have on you. Regular follow-up to check for late effects is important.

Sources: follow-up

For patients · Treatment Option Overview

The following types of treatment are used:

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Radiation therapy

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing.

Sources: x-rays · radiation · cells

External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Sometimes total-body irradiation is given before a stem cell transplant.

Sources: External radiation therapy · total-body irradiation · stem cell transplant

Proton beam radiation therapy is a type of high-energy, external radiation therapy that uses streams of protons (tiny particles with a positive charge) to kill tumor cells. This type of treatment can lower the amount of radiation damage to healthy tissue near a tumor such as the heart or breast.

Sources: Proton beam radiation therapy · protons · tumor · tissue · breast

External radiation therapy is used to treat non-Hodgkin lymphoma, and may also be used as palliative therapy to relieve symptoms and improve quality of life.

Sources: palliative therapy · quality of life

For a pregnant woman with non-Hodgkin lymphoma, radiation therapy should be given after delivery, if possible, to avoid any risk to the fetus. If treatment is needed right away, the woman may decide to continue the pregnancy and receive radiation therapy. A lead shield is used to cover the pregnant woman's abdomen to help protect the fetus from radiation as much as possible.

Sources: lead shield · abdomen

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid (intrathecal chemotherapy), an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). Combination chemotherapy is treatment using two or more anticancer drugs. Steroid drugs may be added, to lessen inflammation and lower the body's immune response.

Sources: drugs · injected · vein · systemic chemotherapy · cerebrospinal fluid · intrathecal chemotherapy · organ · cavity · regional chemotherapy · Combination chemotherapy · Steroid drugs · inflammation · immune response

Systemic combination chemotherapy is used for the treatment of non-Hodgkin lymphoma.

Intrathecal chemotherapy may also be used in the treatment of lymphoma that first forms in the testicles or sinuses (hollow areas) around the nose, diffuse large B-cell lymphoma, Burkitt lymphoma, lymphoblastic lymphoma, and some aggressive T-cell lymphomas. It is given to lessen the chance that lymphoma cells will spread to the brain and spinal cord. This is called CNS prophylaxis.

Sources: lymphoma · testicles · sinuses · diffuse large B-cell lymphoma · Burkitt lymphoma · lymphoblastic lymphoma · aggressive · T-cell lymphomas · spinal cord · CNS prophylaxis

When a pregnant woman is treated with chemotherapy for non-Hodgkin lymphoma, the fetus cannot be protected from being exposed to chemotherapy. Some chemotherapy regimens may cause birth defects if given in the first trimester.

For more information, see Drugs Approved for Non-Hodgkin Lymphoma.

Sources: Drugs Approved for Non-Hodgkin Lymphoma

For patients · Treatment Option Overview / The following types of treatment are used:

Immunotherapy

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

Immunotherapy is a treatment that uses the patient’s immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body’s natural defenses against cancer.

Sources: Immunotherapy · immune system

Immunomodulators: Lenalidomide is an immunomodulator used to treat non-Hodgkin lymphoma.

Sources: Immunomodulators · Lenalidomide

CAR T-cell therapy: The patient's T cells (a type of immune system cell) are changed so they will attack certain proteins on the surface of cancer cells. T cells are taken from the patient and special receptors are added to their surface in the laboratory. The changed cells are called chimeric antigen receptor (CAR) T cells. The CAR T cells are grown in the laboratory and given to the patient by infusion. The CAR T cells multiply in the patient's blood and attack cancer cells. CAR T-cell therapy (such as axicabtagene ciloleucel or tisagenlecleucel) is used to treat large B-cell lymphoma that has not responded to treatment. CAR T-cell therapy is being studied to treat mantle cell lymphoma that has relapsed or not responded to treatment.

Sources: T cells · proteins · receptors · chimeric antigen receptor · infusion · blood · axicabtagene ciloleucel · tisagenlecleucel · B-cell lymphoma · responded · mantle cell lymphoma · relapsed

For more information, see Drugs Approved for Non-Hodgkin Lymphoma.

Sources: Drugs Approved for Non-Hodgkin Lymphoma

For patients · Treatment Option Overview / The following types of treatment are used:

Targeted therapy

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Monoclonal antibody therapy, proteasome inhibitor therapy, and kinase inhibitor therapy are types of targeted therapy used to treat non-Hodgkin lymphoma.

Sources: Monoclonal antibody · therapy · proteasome inhibitor · kinase inhibitor

Monoclonal antibody therapy: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. Types of monoclonal antibodies include:

Sources: immune system · antibodies · infusion · toxins · radioactive

Monoclonal antibody therapy: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. Types of monoclonal antibodies include:

Rituximab, used to treat many types of non-Hodgkin lymphoma.

Sources: Rituximab

Obinutuzumab, used to treat follicular lymphoma.

Sources: Obinutuzumab · follicular lymphoma

Mogamulizumab, used to treat certain types of relapsed or refractory T-cell lymphoma.

Sources: Mogamulizumab · relapsed · refractory · T-cell lymphoma

Tafasitamab combined with lenalidomide to treat relapsed or refractory diffuse large B-cell lymphoma.

Sources: Tafasitamab

Pembrolizumab to treat primary mediastinal large B-cell lymphoma.

Sources: Pembrolizumab · primary mediastinal large B-cell lymphoma

Polatuzumab vedotin, combined with bendamustine and rituximab to treat relapsed or refractory diffuse large B-cell lymphoma.

Sources: Polatuzumab vedotin · bendamustine · diffuse large B-cell lymphoma

Brentuximab vedotin, which contains a monoclonal antibody that binds to a protein called CD30 that is found on some lymphoma cells. It also contains an anticancer drug that may help kill cancer cells.

Sources: Brentuximab vedotin · CD30

Yttrium Y 90-ibritumomab tiuxetan, an example of a radiolabeled monoclonal antibody.

Sources: Yttrium Y 90-ibritumomab tiuxetan · radiolabeled

Mosunetuzumab, which is a bispecific monoclonal antibody that helps the body's immune system recognize and kill cancer cells. It is used to treat relapsed or refractory follicular lymphoma.

Sources: Mosunetuzumab · bispecific monoclonal antibody

Proteasome inhibitor therapy: This treatment blocks the action of proteasomes in cancer cells. Proteasomes remove proteins no longer needed by the cell. When the proteasomes are blocked, the proteins build up in the cell and may cause the cancer cell to die. Bortezomib or ixazomib is used to decrease how much immunoglobulin M is in the blood after cancer treatment for lymphoplasmacytic lymphoma (Waldenström macroglobulinemia). It is also being studied to treat relapsed mantle cell lymphoma.

Sources: proteins · Bortezomib · ixazomib · immunoglobulin · lymphoplasmacytic lymphoma · relapsed · mantle cell lymphoma

Kinase inhibitor therapy: This treatment blocks certain proteins, which may help keep lymphoma cells from growing and may kill them. Kinase inhibitor therapies include:

Kinase inhibitor therapy: This treatment blocks certain proteins, which may help keep lymphoma cells from growing and may kill them. Kinase inhibitor therapies include:

Ibrutinib, acalabrutinib, and zanubrutinib, which are types of Bruton tyrosine kinase inhibitor therapy. They are used to treat mantle cell lymphoma. Ibrutinib and acalabrutinib are also used to treat lymphoplasmacytic lymphoma, and zanubrutinib is being studied to treat it.

Sources: Ibrutinib · acalabrutinib · zanubrutinib · tyrosine kinase inhibitor

Histone methyltransferase inhibitor therapy: Tazemetostat is used to treat follicular lymphoma that has come back or has not gotten better with other treatment. It is used in adults whose cancer has a certain mutation (change) in the EZH2 gene that has already been treated with at least two other anticancer therapies.

Sources: Histone methyltransferase inhibitor · Tazemetostat · mutation · EZH2 gene

B-cell lymphoma-2 (BCL-2) inhibitor therapy: Venetoclax may be used to treat mantle cell lymphoma. It blocks the action of a protein called BCL-2 and may help kill cancer cells.

Sources: B-cell lymphoma-2 · Venetoclax

For more information, see Drugs Approved for Non-Hodgkin Lymphoma.

Sources: Drugs Approved for Non-Hodgkin Lymphoma

For patients · Treatment Option Overview / The following types of treatment are used:

Plasmapheresis

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

If the blood becomes thick with extra antibody proteins and affects circulation, plasmapheresis is done to remove extra plasma and antibody proteins from the blood. In this procedure, blood is removed from the patient and sent through a machine that separates the plasma (the liquid part of the blood) from the blood cells. The patient's plasma contains the unneeded antibodies and is not returned to the patient. The normal blood cells are returned to the bloodstream along with donated plasma or a plasma replacement. Plasmapheresis does not keep new antibodies from forming.

Sources: circulation · plasmapheresis · plasma · donated

For patients · Treatment Option Overview / The following types of treatment are used:

Watchful waiting

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

Watchful waiting is closely monitoring a patient’s condition without giving any treatment until signs or symptoms appear or change.

Sources: Watchful waiting · monitoring · condition

For patients · Treatment Option Overview / The following types of treatment are used:

Antibiotic therapy

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

Antibiotic therapy is a treatment that uses drugs to treat infections and cancer caused by bacteria and other microorganisms.

Sources: Antibiotic · infections · bacteria · microorganisms

For patients · Treatment Option Overview / The following types of treatment are used:

Surgery

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

Surgery may be used to remove the lymphoma in certain patients with indolent or aggressive non-Hodgkin lymphoma.

Sources: Surgery · indolent · aggressive

The type of surgery used depends on where the lymphoma formed in the body:

Local excision for certain patients with mucosa-associated lymphoid tissue (MALT) lymphoma, PTLD, and small bowel T-cell lymphoma.

Sources: excision · mucosa-associated lymphoid tissue (MALT) lymphoma

Splenectomy for patients with marginal zone lymphoma of the spleen.

Sources: Splenectomy · marginal zone lymphoma · spleen

Patients who have a heart, lung, liver, kidney, or pancreas transplant usually need to take drugs to suppress their immune system for the rest of their lives. Long-term immunosuppression after an organ transplant can cause a certain type of non-Hodgkin lymphoma called posttransplant lymphoproliferative disorder (PLTD).

Sources: lung · liver · kidney · pancreas · transplant · immunosuppression · posttransplant lymphoproliferative disorder

Small bowel surgery is often needed to diagnose celiac disease in adults who develop a type of T-cell lymphoma.

Sources: bowel · diagnose · celiac disease

For patients · Treatment Option Overview / The following types of treatment are used:

Stem cell transplant

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

Stem cell transplant is a method of giving high doses of chemotherapy and/or total-body irradiation and then replacing blood-forming cells destroyed by the cancer treatment. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient (autologous transplant) or a donor (allogeneic transplant) and are frozen and stored. After the chemotherapy and/or radiation therapy is completed, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body’s blood cells.

Sources: doses · Stem cells · bone marrow · autologous transplant · donor · allogeneic transplant

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.

Sources: NCI website

For patients · Treatment Option Overview / New types of treatment are being tested in clinical trials.

Vaccine therapy

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

Vaccine therapy is a cancer treatment that uses a substance or group of substances to stimulate the immune system to find the tumor and kill it.

Sources: Vaccine therapy · tumor

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Treatment Option Overview

Follow-up tests may be needed.

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

For patients

Treatment of Indolent Non-Hodgkin Lymphoma

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of indolent stage I and indolent, contiguous stage II non-Hodgkin lymphoma may include the following:

Sources: indolent · stage I · contiguous · stage II · non-Hodgkin lymphoma

Radiation therapy.

Sources: Radiation therapy

Monoclonal antibody therapy (rituximab) and/or chemotherapy.

Sources: Monoclonal antibody · therapy · rituximab · chemotherapy

Watchful waiting.

Sources: Watchful waiting

If the tumor is too large to be treated with radiation therapy, the treatment options for indolent, noncontiguous stage II, III, or IV non-Hodgkin lymphoma will be used.

Sources: tumor · noncontiguous · stage II · III · IV

Treatment of indolent, noncontiguous stage II, III, or IV non-Hodgkin lymphoma may include the following:

Watchful waiting for patients who do not have signs or symptoms.

Sources: signs · symptoms

Monoclonal antibody therapy (rituximab) with or without chemotherapy.

Lenalidomide and rituximab.

Sources: Lenalidomide

Maintenance therapy with rituximab.

Sources: Maintenance therapy

Monoclonal antibody therapy (obinutuzumab) with or without chemotherapy.

Sources: obinutuzumab

EZH2 inhibitor therapy (tazemetostat).

Sources: EZH2 · tazemetostat

Radiolabeled monoclonal antibody therapy.

Sources: Radiolabeled

A clinical trial of high-dose chemotherapy with or without total-body irradiation or radiolabeled monoclonal antibody therapy, followed by autologous or allogeneic stem cell transplant.

Sources: clinical trial · high-dose chemotherapy · total-body irradiation · autologous · allogeneic stem cell transplant

A clinical trial of chemotherapy with or without vaccine therapy.

Sources: vaccine therapy

A clinical trial of new types of monoclonal antibodies.

A clinical trial of radiation therapy that includes nearby lymph nodes, for patients who have stage III disease.

Sources: lymph nodes

A clinical trial of low-dose radiation therapy, to relieve symptoms and improve quality of life.

Sources: low-dose radiation therapy · quality of life

Other treatments for indolent non-Hodgkin lymphoma depend on the type of non-Hodgkin lymphoma. Treatment may include the following:

For follicular lymphoma, treatment may be within a clinical trial of new monoclonal antibody therapy, new chemotherapy regimen, or a stem cell transplant.

Sources: follicular lymphoma · regimen · stem cell transplant

For lymphoplasmacytic lymphoma (Waldenström macroglobulinemia), tyrosine kinase inhibitor therapy and/or plasmapheresis or proteasome inhibitor therapy (if needed to make the blood thinner) is used. Other treatments that are like those used for follicular lymphoma may also be given.

Sources: lymphoplasmacytic lymphoma · tyrosine kinase inhibitor · plasmapheresis · proteasome inhibitor · blood

For gastric mucosa-associated lymphoid tissue (MALT) lymphoma, antibiotic therapy to treat Helicobacter pylori infection is given first. For tumors that do not respond to antibiotic therapy, treatment is radiation therapy, surgery, or rituximab with or without chemotherapy.

Sources: gastric · mucosa-associated lymphoid tissue (MALT) lymphoma · antibiotic · Helicobacter pylori · infection · respond · surgery

For extragastric MALT lymphoma of the eye and Mediterranean abdominal lymphoma, antibiotic therapy is used to treat infection.

Sources: abdominal · lymphoma

For splenic marginal zone lymphoma, rituximab with or without chemotherapy and B-cell receptor therapy is used as initial treatment. If the tumor does not respond to treatment, a splenectomy may be done.

Sources: splenic · marginal zone lymphoma · splenectomy

For patients

Treatment of Aggressive Non-Hodgkin Lymphoma

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of aggressive stage I and aggressive, contiguous stage II non-Hodgkin lymphoma may include the following:

Sources: aggressive · stage I · contiguous · stage II · non-Hodgkin lymphoma

Monoclonal antibody therapy (rituximab) and combination chemotherapy. Sometimes radiation therapy is given later.

Sources: Monoclonal antibody · therapy · rituximab · combination chemotherapy · radiation therapy

A clinical trial of a new regimen of monoclonal antibody therapy and combination chemotherapy.

Sources: clinical trial · regimen

Treatment of aggressive, noncontiguous stage II, III, or IV non-Hodgkin lymphoma may include the following:

Sources: noncontiguous · stage II · III · IV

Monoclonal antibody therapy (rituximab) with combination chemotherapy.

Combination chemotherapy.

A clinical trial of monoclonal antibody therapy with combination chemotherapy followed by radiation therapy.

Other treatments depend on the type of aggressive non-Hodgkin lymphoma. Treatment may include the following:

For extranodal NK-/T-cell lymphoma, radiation therapy that may be given before, during, or after chemotherapy and CNS prophylaxis.

Sources: extranodal · NK · T-cell lymphoma · chemotherapy · CNS prophylaxis

For mantle cell lymphoma, monoclonal antibody therapy with combination chemotherapy, followed by stem cell transplant. Monoclonal antibody therapy may be given afterwards as maintenance therapy (treatment that is given after initial therapy to help keep cancer from coming back).

Sources: mantle cell lymphoma · stem cell transplant · maintenance therapy

For posttransplantation lymphoproliferative disorder, treatment with immunosuppressive drugs may be stopped. If this does not work or cannot be done, monoclonal antibody therapy alone or with chemotherapy may be given. For cancer that has not spread, surgery to remove the cancer or radiation therapy may be used.

Sources: posttransplantation lymphoproliferative disorder · immunosuppressive · drugs · cancer · surgery

For plasmablastic lymphoma, treatments are like those used for lymphoblastic lymphoma or Burkitt lymphoma.

Sources: plasmablastic lymphoma · lymphoblastic lymphoma · Burkitt lymphoma

For information on the treatment of lymphoblastic lymphoma, see Treatment Options for Lymphoblastic Lymphoma and for information on the treatment of Burkitt lymphoma, see Treatment Options for Burkitt Lymphoma.

Sources: Treatment Options for Lymphoblastic Lymphoma · Treatment Options for Burkitt Lymphoma

For patients

Treatment of Lymphoblastic Lymphoma

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of lymphoblastic lymphoma may include the following:

Sources: lymphoblastic lymphoma

Combination chemotherapy and CNS prophylaxis. Sometimes radiation therapy is also given to shrink a large tumor.

Sources: Combination chemotherapy · CNS prophylaxis · radiation therapy · tumor

Targeted therapy with a monoclonal antibody alone (rituximab) or combined with kinase inhibitor therapy (ibrutinib).

Sources: Targeted therapy · monoclonal antibody · rituximab · kinase inhibitor · therapy · ibrutinib

A clinical trial of stem cell transplant after initial treatment.

Sources: clinical trial · stem cell transplant

For patients

Treatment of Burkitt Lymphoma

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of Burkitt lymphoma may include the following:

Sources: Burkitt lymphoma

Combination chemotherapy with or without monoclonal antibody therapy.

Sources: Combination chemotherapy · monoclonal antibody · therapy

CNS prophylaxis.

Sources: CNS prophylaxis

For patients

Treatment of Recurrent Non-Hodgkin Lymphoma

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of indolent, recurrent non-Hodgkin lymphoma may include the following:

Sources: indolent · recurrent · non-Hodgkin lymphoma

Monoclonal antibody therapy (rituximab or obinutuzumab) with or without chemotherapy.

Sources: Monoclonal antibody · therapy · rituximab · obinutuzumab · chemotherapy

Lenalidomide and rituximab.

Sources: Lenalidomide

EZH2 inhibitor therapy (tazemetostat).

Sources: EZH2 · tazemetostat

Radiation therapy as palliative therapy to relieve symptoms and improve quality of life.

Sources: Radiation therapy · palliative therapy · symptoms · quality of life

Chemotherapy with one or more drugs.

Sources: Chemotherapy · drugs

Radiolabeled monoclonal antibody therapy.

Sources: Radiolabeled

CAR T-cell therapy.

Sources: CAR T-cell therapy

Bispecific monoclonal antibody therapy (mosunetuzumab).

Sources: Bispecific monoclonal antibody · mosunetuzumab

Stem cell transplant.

Sources: Stem cell transplant

Treatment of aggressive, recurrent non-Hodgkin lymphoma may include the following:

Sources: aggressive

CAR T-cell therapy with axicabtagene ciloleucel for primary refractory disease or relapse within 1 year.

Sources: CAR T-cell therapy · axicabtagene ciloleucel · primary · refractory · relapse

Bone marrow transplant or stem cell transplant consolidation therapy.

Sources: Bone marrow transplant · consolidation therapy

CAR T-cell therapy for relapse after autologous stem cell transplant.

Sources: autologous

Tafasitamab plus lenalidomide.

Sources: Tafasitamab

Rituximab plus lenalidomide.

Polatuzumab vedotin plus rituximab and bendamustine.

Sources: Polatuzumab vedotin · bendamustine

Loncastuximab tesirine.

Sources: Loncastuximab tesirine

Bispecific monoclonal antibody therapy (mosunetuzumab).

Chemotherapy with or without stem cell transplant.

Sources: stem cell transplant

For certain T-cell lymphomas, monoclonal antibody therapy with mogamulizumab.

Sources: T-cell lymphomas · mogamulizumab

Monoclonal antibody therapy with or without combination chemotherapy followed by autologous stem cell transplant.

Sources: combination chemotherapy

Radiation therapy as palliative therapy to relieve symptoms and improve quality of life.

Radiolabeled monoclonal antibody therapy.

For mantle cell lymphoma, treatment may include the following:

Sources: mantle cell lymphoma

For mantle cell lymphoma, treatment may include the following:

Bruton tyrosine kinase inhibitor therapy.

Sources: tyrosine kinase inhibitor

Rituximab with or without a tyrosine kinase inhibitor (ibrutinib).

Sources: ibrutinib

Lenalidomide.

Sources: Lenalidomide

A clinical trial of lenalidomide with monoclonal antibody therapy.

A clinical trial comparing lenalidomide to other therapy.

A clinical trial of proteasome inhibitor therapy (bortezomib).

Sources: proteasome inhibitor · bortezomib

For diffuse large B-cell lymphoma, treatment may include the following:

Sources: diffuse large B-cell lymphoma

For diffuse large B-cell lymphoma, treatment may include the following:

Tafasitamab plus lenalidomide.

Polatuzumab vedotin, combined with bendamustine and rituximab.

A clinical trial of autologous or allogeneic stem cell transplant.

Treatment of indolent lymphoma that comes back as aggressive lymphoma depends on the type of non-Hodgkin lymphoma and may include radiation therapy as palliative therapy to relieve symptoms and improve quality of life. Treatment of aggressive lymphoma that comes back as indolent lymphoma may include chemotherapy.

Sources: indolent lymphoma · aggressive lymphoma

For patients

Treatment of Non-Hodgkin Lymphoma During Pregnancy

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

For patients · Treatment of Non-Hodgkin Lymphoma During Pregnancy

Indolent Non-Hodgkin Lymphoma During Pregnancy

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

Women who have indolent (slow-growing) non-Hodgkin lymphoma during pregnancy may be treated with watchful waiting until after they give birth. (See the Treatment Options for Indolent Non-Hodgkin Lymphoma section for more information.)

Sources: indolent · non-Hodgkin lymphoma · pregnancy · watchful waiting · Treatment Options for Indolent Non-Hodgkin Lymphoma

For patients · Treatment of Non-Hodgkin Lymphoma During Pregnancy

Aggressive Non-Hodgkin Lymphoma During Pregnancy

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024. Captured 2026-09-09.

Treatment of aggressive non-Hodgkin lymphoma during pregnancy may include the following:

Sources: aggressive · non-Hodgkin lymphoma · pregnancy

Treatment given right away based on the type of non-Hodgkin lymphoma to increase the mother's chance of survival. Treatment may include combination chemotherapy and rituximab.

Sources: survival · combination chemotherapy · rituximab

Early delivery of the baby followed by treatment based on the type of non-Hodgkin lymphoma.

If in the first trimester of pregnancy, medical oncologists may advise ending the pregnancy so that treatment may begin. Treatment depends on the type of non-Hodgkin lymphoma.

Sources: medical oncologists

Studies

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients

NCT00103610 · COMPLETED · phase3

Lymphoma, Non-Hodgkin

ClinicalTrials.gov record

Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab

NCT00139841 · COMPLETED · phase3

Non-Hodgkin's Lymphoma

ClinicalTrials.gov record

Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy

NCT00185393 · COMPLETED · phase3

Lymphoma, Non-Hodgkin

ClinicalTrials.gov record

A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma

NCT01200758 · COMPLETED · phase3

Non-Hodgkin's Lymphoma

ClinicalTrials.gov record

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

NCT01283516 · COMPLETED · phase1

Tumors Characterized by Genetic Abnormalities of ALK

ClinicalTrials.gov record

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

NCT01732913 · TERMINATED · phase3

Indolent Non-Hodgkin's Lymphomas

ClinicalTrials.gov record

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

NCT01732926 · TERMINATED · phase3

Indolent Non-Hodgkin's Lymphomas

ClinicalTrials.gov record

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

NCT01777152 · COMPLETED · phase3

Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma

ClinicalTrials.gov record

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

NCT01996865 · COMPLETED · phase3

Lymphoma, Non-Hodgkin

ClinicalTrials.gov record

Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia

NCT02165397 · COMPLETED · phase3

Waldenström's Macroglobulinemia

ClinicalTrials.gov record

A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT02500407 · COMPLETED · phase1, phase2

Lymphocytic Leukemia, Chronic, Lymphoma, Non Hodgkin

ClinicalTrials.gov record

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)

NCT02576990 · COMPLETED · phase2

Mediastinal Large B-cell Lymphoma, Richter Syndrome

ClinicalTrials.gov record

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

NCT02703272 · TERMINATED · phase3

Lymphoma, Non-Hodgkin

ClinicalTrials.gov record

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

NCT03075696 · ACTIVE NOT RECRUITING · phase1, phase2

Non-Hodgkin's Lymphoma

ClinicalTrials.gov record

A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

NCT03105336 · COMPLETED · phase2

Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-Hodgkin Lymphoma

ClinicalTrials.gov record

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

NCT03483103 · COMPLETED · phase2

Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

ClinicalTrials.gov record

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

NCT03575351 · COMPLETED · phase3

Lymphoma, Non-Hodgkin

ClinicalTrials.gov record

Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS

NCT00025662 · COMPLETED · phase2

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Leukemia, Myeloid, Leukemia, Myelomonocytic, Chronic, Leukemia, Lymphocytic, Lymphoma, Lymphoma, Mantle-cell,...

ClinicalTrials.gov record

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia

NCT00060346 · TERMINATED · phase2

Lymphoma

ClinicalTrials.gov record

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies

NCT00079391 · COMPLETED · phase2

Hematologic Malignancies, Bone Marrow Transplant Rejection

ClinicalTrials.gov record

Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies

NCT00241358 · COMPLETED · phase1, phase2

Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Lymphocytic Leukemia, Chronic, Myelodysplastic Syndromes, Multiple Myeloma, Lymphoma,...

ClinicalTrials.gov record

Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma

NCT00244855 · COMPLETED · phase2

Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Cutaneous B-cell Non-Hodgkin...

ClinicalTrials.gov record

Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma

NCT00248534 · TERMINATED · phase2

Lymphoma

ClinicalTrials.gov record

A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation

NCT00275262 · TERMINATED · phase2

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mantle Cell Lymphoma

ClinicalTrials.gov record

Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma

NCT00278161 · COMPLETED · phase2

Leukemia, Lymphoma

ClinicalTrials.gov record

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

NCT00295932 · COMPLETED · phase1, phase2

Leukemia, Lymphoma

ClinicalTrials.gov record

Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients

NCT00322387 · COMPLETED · phase2

Lymphoma, Non-Hodgkin, Multiple Myeloma

ClinicalTrials.gov record

Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

NCT00322491 · COMPLETED · phase2

Lymphoma, Non-Hodgkin, Multiple Myeloma

ClinicalTrials.gov record

Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

NCT00322842 · COMPLETED · phase2

Lymphoma, Non-Hodgkin, Multiple Myeloma

ClinicalTrials.gov record

Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

NCT00345865 · COMPLETED · phase2

Lymphoma

ClinicalTrials.gov record

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

NCT00392834 · COMPLETED · phase2

Lymphoma

ClinicalTrials.gov record

Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma

NCT00392990 · COMPLETED · phase2

Lymphoma

ClinicalTrials.gov record

Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor

NCT00393380 · TERMINATED · phase2

Leukemia, Myeloid, Chronic, Anemia, Aplastic, Myelofibrosis, Lymphoma, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute

ClinicalTrials.gov record

AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone

NCT00395967 · TERMINATED · phase2

Multiple Myeloma, Lymphoma, Non-Hodgkin's

ClinicalTrials.gov record

AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF

NCT00396266 · COMPLETED · phase2

Multiple Myeloma, Lymphoma, Non-Hodgkin

ClinicalTrials.gov record

Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells

NCT00398411 · COMPLETED · phase3

Hodgkin Disease, Non-Hodgkin Lymphoma, Multiple Myeloma, Bacteremia

ClinicalTrials.gov record

Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen

NCT00556452 · COMPLETED · phase1, phase2

Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome

ClinicalTrials.gov record

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

NCT00566696 · COMPLETED · phase2

Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML), Juvenile Myelomonocytic Leukemia (JMML), Hemoglobinuria, Paroxysmal Nocturnal...

ClinicalTrials.gov record

Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin

NCT00577798 · COMPLETED · Phase not reported

Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Lymphoma

ClinicalTrials.gov record

Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma

NCT00596154 · COMPLETED · phase2

CNS Lymphoma, CNS Brain Cancer, Non-Hodgkin's Lymphoma

ClinicalTrials.gov record

Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant

NCT00597714 · COMPLETED · phase2

Hodgkin's Disease, Non Hodgkin's Lymphoma, Myeloma, Leukemia, Myelodysplasia

ClinicalTrials.gov record

Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma

NCT00724984 · COMPLETED · phase1, phase2

Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin

ClinicalTrials.gov record

Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma

NCT00784927 · COMPLETED · phase2

Lymphoma

ClinicalTrials.gov record

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

NCT00787527 · COMPLETED · phase1, phase2

Lymphoma

ClinicalTrials.gov record

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

NCT00810576 · TERMINATED · phase2

Lymphoma

ClinicalTrials.gov record

CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma

NCT00893516 · TERMINATED · phase2

T-cell Lymphoma

ClinicalTrials.gov record

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

NCT00989586 · COMPLETED · phase1, phase2

Lymphoma

ClinicalTrials.gov record

Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients

NCT01018979 · COMPLETED · phase2

Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease

ClinicalTrials.gov record

Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

NCT01076543 · COMPLETED · phase1, phase2

AIDS-Related Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Marginal Zone Lymphoma,...

ClinicalTrials.gov record

Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab

NCT01119794 · TERMINATED · phase2

Lymphoma, Non-Hodgkins

ClinicalTrials.gov record

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

NCT01158118 · COMPLETED · phase2

Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Lymphoma, Non-Hodgkin, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Multiple Myeloma

ClinicalTrials.gov record

High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma

NCT01182415 · COMPLETED · phase2

Non-Hodgkin's Lymphoma, CNS Lymphoma

ClinicalTrials.gov record

The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma

NCT01235793 · TERMINATED · phase2

B-Cell Lymphoma Originating in the CNS

ClinicalTrials.gov record

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

NCT01318317 · ACTIVE NOT RECRUITING · phase1, phase2

Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma

ClinicalTrials.gov record

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

NCT01381692 · COMPLETED · phase1, phase2

Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent...

ClinicalTrials.gov record

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

NCT01445535 · COMPLETED · phase1

T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, NK T-Cell Lymphoma

ClinicalTrials.gov record

Unrelated Umbilical Cord Blood (UBC)Transplantation

NCT01768845 · COMPLETED · na

Chronic Myelogenous Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome, Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Chronic Lymphocytic...

ClinicalTrials.gov record

A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)

NCT01804166 · COMPLETED · phase4

Hepatosplenic T-Cell Lymphoma

ClinicalTrials.gov record

Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies

NCT01947140 · TERMINATED · phase1, phase2

Lymphoid Malignancies, Multiple Myeloma, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma

ClinicalTrials.gov record

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma

NCT01973062 · TERMINATED · phase2

Primary Central Nervous System Non-Hodgkin Lymphoma

ClinicalTrials.gov record

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

NCT01998035 · TERMINATED · phase1, phase2

Lymphoid Malignancies, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma

ClinicalTrials.gov record

Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

NCT02098109 · COMPLETED · phase2

Multiple Myeloma, Lymphoma, Non-Hodgkin

ClinicalTrials.gov record

PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients

NCT02104427 · COMPLETED · phase2

Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease

ClinicalTrials.gov record

Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma

NCT02257242 · COMPLETED · phase1

Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Small-Cell, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

ClinicalTrials.gov record

Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT02420795 · TERMINATED · phase1, phase2

Central Nervous System Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Refractory...

ClinicalTrials.gov record

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

NCT02535247 · TERMINATED · phase1, phase2

Lymphoma, T-Cell, Peripheral

ClinicalTrials.gov record

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

NCT02567656 · COMPLETED · phase1

Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous

ClinicalTrials.gov record

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

NCT02595866 · COMPLETED · phase1

AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi...

ClinicalTrials.gov record

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

NCT02797470 · ACTIVE NOT RECRUITING · phase1, phase2

HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Burkitt...

ClinicalTrials.gov record

A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer

NCT02797964 · COMPLETED · phase1, phase2

Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)

ClinicalTrials.gov record

Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma

NCT02823327 · TERMINATED · Phase not reported

AIDS-Related Primary Effusion Lymphoma

ClinicalTrials.gov record

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

NCT03049449 · COMPLETED · phase1

Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Extranodal NK-T-Cell, Lymphoma, T-Cell, Peripheral

ClinicalTrials.gov record

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

NCT03113500 · ACTIVE NOT RECRUITING · phase2

Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Angioimmunoblastic T-Cell Lymphoma, Ann Arbor Stage...

ClinicalTrials.gov record

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

NCT03133221 · COMPLETED · phase2

Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma, B-cell Lymphoma, Transformed Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Small Lymphocytic...

ClinicalTrials.gov record

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

NCT03364231 · COMPLETED · phase2

Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Non Follicular Indolent Non-Hodgkin Lymphoma

ClinicalTrials.gov record

Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma

NCT03590574 · TERMINATED · phase1, phase2

T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma

ClinicalTrials.gov record

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

NCT03598998 · ACTIVE NOT RECRUITING · phase1, phase2

Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma,...

ClinicalTrials.gov record

Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health

NCT04000880 · COMPLETED · na

Breast Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer, Multiple Myeloma, Ovary Cancer, Prostate Cancer, Thyroid Cancer, Non-Hodgkin Lymphoma

ClinicalTrials.gov record

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

NCT04074746 · COMPLETED · phase1, phase2

Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Peripheral T-Cell...

ClinicalTrials.gov record

Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

NCT04251065 · TERMINATED · phase2

Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma

ClinicalTrials.gov record

Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

NCT04459416 · ACTIVE NOT RECRUITING · phase3

Multiple Myeloma, Hodgkin Disease, Non-Hodgkin Lymphoma

ClinicalTrials.gov record

Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer

NCT04478123 · COMPLETED · phase2

Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, HDT-AHCT

ClinicalTrials.gov record

An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

NCT05011058 · TERMINATED · phase2

Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS, EBV-Related Hodgkin Lymphoma, EBV-Related PTLD,...

ClinicalTrials.gov record

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

NCT05255601 · TERMINATED · phase1, phase2

Lymphoma, Non-Hodgkin, Hodgkin Disease

ClinicalTrials.gov record

Disease and treatment settings

High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements

Disease and treatment setting

High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements

High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements

Disease and treatment setting

High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements

High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements

Disease and treatment setting

High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements

High Grade B-Cell Lymphoma, Not Otherwise Specified

Disease and treatment setting

High Grade B-Cell Lymphoma, Not Otherwise Specified

Non-Hodgkin Lymphoma

Disease and treatment setting

Non-Hodgkin Lymphoma

recurrent Non-Hodgkin Lymphoma

Disease and treatment setting

Non-Hodgkin lymphomas may be grouped for treatment according to whether the cancer is indolent or aggressive, whether affected lymph nodes are next to each other in the body, and whether the cancer is newly diagnosed or recurrent.

recurrent Non-Hodgkin Lymphoma

Disease and treatment setting

Treatment of Recurrent Non-Hodgkin Lymphoma

Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma

Disease and treatment setting

Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma

Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma

Disease and treatment setting

Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma

Riabni: refractory Non-Hodgkin's Lymphoma

Disease and treatment setting

1.1 Non-Hodgkin's Lymphoma (NHL) RIABNI is indicated for the treatment of adult patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.

Rituxan: refractory Non-Hodgkin's Lymphoma

Disease and treatment setting

1.1 Non–Hodgkin's Lymphoma (NHL) RITUXAN is indicated for the treatment of adult patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.

Ruxience: refractory Non-Hodgkin's Lymphoma (first-line) after prior therapy

Disease and treatment setting

• Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). o Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. o Previously untreated follicular, CD20-positive, B-cell NHL in combination with...

Small Intestinal Lymphoma

Disease and treatment setting

Small Intestinal Lymphoma

Truxima: refractory Non-Hodgkin's Lymphoma

Disease and treatment setting

1.1 Non–Hodgkin's Lymphoma (NHL) TRUXIMA (rituximab-abbs) is indicated for the treatment of adult patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.

Zevalin: refractory Non-Hodgkin's Lymphoma

Disease and treatment setting

1.1 Relapsed or Refractory, Low-grade or Follicular NHL Zevalin is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL).

Zevalin: refractory Non-Hodgkin's Lymphoma (first-line)

Disease and treatment setting

1 INDICATIONS AND USAGE Zevalin is a CD20-directed radiotherapeutic antibody administered as part of the Zevalin therapeutic regimen indicated for the treatment of adult patients with: relapsed or refractory, low-grade or follicular...

Zydelig: recurrent non-Hodgkin lymphoma after prior therapy

Disease and treatment setting

For the treatment of relapsed follicular B-cell Non-Hodgkin Lymphoma (FL) in patients who have received at least 2 prior systemic therapies and relapsed small lymphocytic lymphoma (SLL) in patients who have received at least 2 prior...

Drug labels

JYLAMVO

Label date 2026-06-08

JYLAMVO is a folate analog metabolic inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults...

DailyMed label

Zevalin

Label date 2023-04-25

Zevalin is a CD20-directed radiotherapeutic antibody administered as part of the Zevalin therapeutic regimen indicated for the treatment of adult patients with: relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's...

DailyMed label